China’s first 3D printed drug product was approved
International Business News – Nanjing Sandiji Pharmaceutical Technology Co., Ltd, has announced that its first 3D-printed drug product, T19, has received IND approval from the National Medical Products Administration (NMPA). The product is known to be the first 3D-printed pharmaceutical product to receive IND approval in China. T19 is a 3D printed drug independently designed and developed by The Company with global intellectual property rights. It is mainly targeted at the symptoms of rheumatoid arthritis, and its unique timing advantage will provide patients with a better choice of clinical medication.
Comments: Rheumatoid arthritis has huge clinical and market demand in major market countries such as the United States and China. By 2025, it is expected that the global market size will reach 30.7 billion US dollars, which is about 200 billion yuan. Medical 3D printing is a popular direction in the field of 3D printing. There is no doubt that medical 3D printing is a pioneering technology. At present, it has created human living tissue and organs. Now the printed drugs have been successful, and the market and social value in the future are huge.
Among a-share companies, Guangyunda (300227) established Shanghai Guangyunda Digital Medical Technology Co., LTD, which is the first enterprise focusing on medical 3D printing in China. The company has established strategic partnerships with dozens of top third-class hospitals across the country and completed several monumental cases in China’s medical 3D printing industry.The holding subsidiary of Blu-ray Development (600466), Blu-ray Inno, has made progress in three research and development application fields of bio-ink, 3D bio-printer and supporting software system.